KOSDAQMachinery460940

P&S Robotics

₩5,300▲ 1.53%2026-10-02 close

Market Cap

₩71B

Turnover

₩200M

Volume

40,000 shares

Shares out.

13.5M

PER

—

PBR

1.6×

EPS

—

Dividend Yield

0.80%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩40 per share · Prices as of the 2026-10-02 close

Report overview

Rehab Robot Expansion Phase, Earnings Volatility Widens

P&S Robotics continues to expand overseas sales channels centered on its gait rehabilitation robot Walkbot, but quarterly results since the third quarter of 2025 have entered a volatile phase marked by repeated operating losses and swings in net profit.

1
2025 annual revenue rose to KRW 7.64bn year on year, but operating profit fell to KRW 1.00bn, pulling the operating margin down from 22.8% to 13.1%.
2
The company posted operating losses in three consecutive quarters—Q3 2025, Q1 2026, and Q2 2026—though net profit turned positive again in Q2 2026 despite the operating loss.
3
Operating cash flow swung to negative KRW 1.58bn in 2025 from positive KRW 1.21bn in 2024, opening a gap between accounting profit and cash generation.
4
Global competitor Hocoma's parent company DIH ceased operations in November 2025, raising the possibility of replacement demand shifting toward rivals.
5
Backed by a zero-borrowing policy and capital raised since its listing, the debt ratio has fallen to single digits.

Business structure

P&S Robotics is a rehabilitation robotics company founded in 2003 that developed Korea's first gait rehabilitation robot system in 2011 and listed on KOSDAQ in July 2024.

The company changed its name from P&S Mechanics to P&S Robotics in June 2025, a move described as reinforcing its identity as a dedicated robotics firm.

Its flagship product, Walkbot, is a wearable exoskeleton gait rehabilitation robot that simultaneously controls the hip, knee, and ankle joints, offered in adult (S), pediatric (K), global (G), and premium (P) model variants tailored to patient needs.

The company unveiled a new upper-limb rehabilitation product, Healerbot, targeting shoulder, arm, and hand recovery, at the MEDICA medical device trade fair in Düsseldorf, Germany in November 2025, and is also developing Babybot, a gait-assist robot for infants and young children.

Export sales, combining product and maintenance revenue, reportedly account for a high share of total sales, and the company operates a distribution network spanning 15 countries through 27 partner firms.

Under an exclusive agreement with Russia's Stemepiece, the company has supplied increasing annual volumes of Walkbot units from 2023 through 2026.

In the competitive landscape, Switzerland-based Hocoma's parent company DIH, previously the global market leader, ceased operations in November 2025, raising the prospect of industry realignment, with P&S Robotics cited as a domestic alternative given its wearable exoskeleton design and multi-country certifications.

Since listing, the company has maintained a zero-borrowing policy funded by IPO proceeds and internal cash, and in October 2025 it approved a 1-for-1 bonus share issuance that expanded the number of outstanding shares.

Earnings trend

Quarterly revenue · Operating profit

₩2.6B₩1.2B25Q2₩800M-₩800M25Q325Q4₩900M-₩400M26Q1₩1.7B-₩500M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩6B₩1.3B2023₩7.1B₩1.6B2024₩7.6B₩1B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩2.6B	₩1.2B	45.8%
2025Q3	₩800M	-₩800M	−104.3%
2025Q4	—	—	—
2026Q1	₩900M	-₩400M	−38.3%
2026Q2	₩1.7B	-₩500M	−26.5%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2023	₩6B	₩1.3B	₩1.4B	22.0%	18.3%	19.1%
2024	₩7.1B	₩1.6B	₩2.3B	22.8%	5.8%	3.4%
2025	₩7.6B	₩1B	₩2.7B	13.1%	6.4%	4.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05

Earnings analysis

Consolidated revenue rose to KRW 7.64bn in 2025 from KRW 7.11bn in 2024, but operating profit actually declined to KRW 1.00bn from KRW 1.62bn, sharply lowering the operating margin from 22.8% to 13.1%.

Net profit attributable to owners, however, rose to KRW 2.75bn from KRW 2.32bn, producing a somewhat unusual pattern of falling operating profit alongside rising net profit.

On a quarterly basis, Q2 2025 was solid with revenue of KRW 2.65bn and operating profit of KRW 1.21bn (an operating margin of roughly 46%), but Q3 saw revenue plunge to KRW 784m, swinging to an operating loss of KRW 818m and a net loss of KRW 156m.

This pattern extended into 2026, with Q1 revenue of KRW 932m and an operating loss of KRW 357m, followed by Q2 revenue of KRW 1.73bn and an operating loss of KRW 458m—marking three consecutive quarters of operating losses.

Notably, Q2 2026 still posted a positive owners' net profit of KRW 218m despite the operating loss, suggesting non-operating items offset the operating shortfall.

The rise in full-year 2025 net profit despite falling operating profit likely reflects a similar non-operating contribution exceeding the decline in operating income.

On the cash flow side, operating cash flow turned negative at KRW -1.58bn in 2025, reversing from positive KRW 1.21bn in 2024 and KRW 807m in 2023, diverging from the reported increase in net profit.

The balance sheet has remained stable, with equity rising sharply from KRW 7.70bn in 2023 to KRW 39.96bn in 2024 following the IPO capital raise, then further to KRW 43.23bn in 2025, while the debt ratio fell from 19.1% in 2023 to 4.3% in 2025.

Industry analysis

The global rehabilitation robotics market, the company's end market, is expected to see structural growth driven by population aging, a rising number of patients with gait impairments from stroke and spinal cord injury, and a shortage of rehabilitation therapists.

Reports citing market research data forecast the global rehabilitation robot industry to grow at a compound annual rate of 17% from 2025 to 2030.

The most notable competitive development has been the November 2025 cessation of operations by DIH, the parent company of Switzerland's Hocoma and the former global market leader, following financial and operational difficulties—a development that could shift existing customers' equipment replacement demand toward other suppliers.

P&S Robotics, with its wearable exoskeleton technology capable of simultaneously controlling the hip, knee, and ankle joints and multi-country certifications including CE MDR, is cited as one of the alternatives amid this market realignment.

The domestic market is tied to government support and health policy, having contracted after related government projects were paused following the martial law crisis, with the company stating it expects the domestic rehabilitation robot market to reactivate with a lag.

Overseas, the company continues to expand its sales network into Russia, India, and Mexico, while diversifying its product portfolio into upper-limb rehabilitation through Healerbot to broaden its historically gait-rehabilitation-centered lineup.

However, the market itself remains composed of a small number of specialized players, keeping overall revenue scale modest and making results susceptible to volatility tied to the timing of individual order wins and deliveries.

Outlook

The company unveiled its Healerbot upper-limb rehabilitation robot at the MEDICA trade fair in Germany in November 2025, stating it plans to launch a personal-use version first, with a hospital-grade successor requiring multi-agency certification to follow in 2027.

Development of Babybot, a device for infants and young children, is also reportedly underway, giving the historically gait-rehabilitation-centered product portfolio potential room to expand into upper-limb and pediatric segments.

Overseas, under its exclusive agreement with Russia's Stemepiece, the company reportedly plans to supply a larger volume of Walkbot units in 2026 than in prior years, while sales discussions continue in new regions including India and Mexico.

A company representative has said it expects domestic rehabilitation robot-related government projects, which contracted after the martial law crisis, to reactivate with a time lag, making the pace of any domestic demand recovery a variable to watch.

The sharp Q3 2025 revenue decline was attributed to a delivery delay to a new customer, with the company indicating the deferred volume would be recognized as revenue in subsequent quarters, making the actual timing and scale of that deferred recognition a key point to monitor in coming quarters.

Whether replacement demand stemming from competitor DIH's operational shutdown translates into actual new contracts also remains to be confirmed.

In addition, with SG&A continuing to rise from hiring, expanded overseas sales efforts, and new-product exhibition and certification costs, whether revenue recovery can offset this growing fixed-cost burden will likely determine the direction of the operating margin going forward.

Valuation

PER

—

PBR

1.6×

ROE

6.4%

EPS

—

BPS

₩3,213

Dividend per share

₩40

The current share price trades at a premium to book value per share, which can be read as partly reflecting accumulated growth expectations since the company's listing.

However, given three consecutive quarters of operating losses starting in Q3 2025, recent quarterly results alone make it difficult to derive stable earnings-based multiples.

On the dividend side, per-share cash dividends have continued, but the yield level remains modest, as is common for a growth-oriented small-cap name.

Annual results present a mixed picture, combining the positive signals of revenue growth and rising net profit with the offsetting signals of a declining operating margin and a swing to negative operating cash flow, meaning that interpreting valuation requires accounting for both quarterly volatility and the influence of one-off items.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05

Bull factors

Potential Beneficiary of Leading Global Rival's Exit

Following the November 2025 shutdown of DIH, the parent of former global leader Hocoma, due to financial and operational difficulties, there is a possibility that replacement demand for aging installed equipment could shift toward other suppliers.

P&S Robotics, with a comparable wearable exoskeleton design and multi-country certifications including CE MDR, is cited as a domestic alternative in this context. However, how much and how soon this potential benefit translates into actual new contracts remains to be confirmed.

Product Portfolio Diversification

Building on its gait rehabilitation robot Walkbot, the company expanded its lineup by unveiling the upper-limb rehabilitation robot Healerbot at the MEDICA trade fair in Germany in November 2025.

Development of Babybot, a device for infants and young children, is also reportedly underway, giving future revenue potential to diversify beyond gait rehabilitation alone. That said, the commercialization timing and revenue contribution of these new products remain unverified.

Zero-Debt Structure and Capital Buffer

Since its listing, the company has maintained a zero-borrowing policy, funding operations through IPO proceeds and internal cash, with the debt ratio falling from 19.1% in 2023 to 4.3% in 2025. Equity continued to grow after the post-IPO capital increase, rising from KRW 39.96bn in 2024 to KRW 43.23bn in 2025. This financial buffer could support investments such as new product development and overseas sales expansion.

Bear factors

Three Consecutive Quarters of Operating Losses

Operating losses persisted across three consecutive quarters: KRW -818m in Q3 2025, KRW -357m in Q1 2026, and KRW -458m in Q2 2026. Even though Q2 revenue of KRW 1.73bn exceeded Q1's KRW 932m, the operating loss actually widened, indicating that the pace of revenue recovery has yet to catch up with rising costs. How long this pattern persists is a key variable for future results.

Operating Cash Flow Turned Negative

Operating cash flow swung to negative KRW 1.58bn in 2025, reversing from positive KRW 1.21bn in 2024 and KRW 807m in 2023. Even as accounting net profit rose, actual cash generation declined, potentially reflecting a buildup in inventory or receivables tied to the project-based revenue recognition structure. Whether cash flow improves needs to be confirmed in subsequent quarters.

Policy Dependence of Domestic Demand

Domestic demand for rehabilitation robots is tied in part to government support programs and health policy, and related government projects contracted after being paused following the martial law crisis.

While the company has said it expects the domestic market to reactivate with a lag, the timing and scale of that reactivation remain uncertain. As a result, revenue continues to rely substantially on overseas sales.

Risk factors

Revenue Recognition and Quarterly Volatility

Because high-value medical devices are recognized as revenue only after advance payment, shipment, and inspection, quarterly results can swing sharply depending on individual contract delivery timing. In Q3 2025, revenue fell sharply due to a delivery delay to a new customer.

Distinguishing whether a weak quarter reflects underlying business deterioration or a temporary shift in delivery timing is important.

New Product Commercialization Timeline Risk

The Healerbot upper-limb rehabilitation robot is planned to launch first in a personal-use version, with a hospital-grade successor targeted for 2027, meaning revenue contribution depends on completing medical device certification processes across multiple countries.

Babybot remains in development, and commercialization timing could slip. R&D and exhibition costs tied to new products are recognized in SG&A ahead of any revenue contribution, which can weigh on profitability during the interim period.

External Exposure from High Overseas Revenue Share

With a sales network spanning countries including Russia, India, and Mexico, revenue recognition timing and scale can be affected by exchange rates, trade conditions, and regulatory certification changes in individual markets.

While exclusive contract structures with certain countries help secure stable volumes, they also carry concentration risk tied to the counterparty's own circumstances.

A global competitor's market exit does not necessarily benefit this company alone, and the possibility that other rivals capture the replacement demand instead cannot be ruled out.

What to watch next

Around November 2026
Check the Q3 2026 earnings disclosure to see whether the three-quarter streak of operating losses continues or shows signs of improvement.
Q4 2026
Verify whether deferred delivery volumes from Q3 2025 and any new orders are actually recognized as revenue during Q4, which the company has cited as a seasonally strong quarter.
Within 2026
Track the fulfillment status of the planned Walkbot supply volume to Russia's Stemepiece under the exclusive contract for 2026, as well as whether new sales agreements are signed in regions such as India and Mexico.
2027
Whether the certification and launch schedule for the hospital-grade successor version of Healerbot proceeds as planned is a key point to watch for the company's longer-term portfolio expansion.
Upcoming quarterly disclosures
Given that operating cash flow turned negative in 2025, it is worth monitoring whether cash flow realigns with accounting profit in coming quarters.

Overall view

P&S Robotics has built out its overseas sales channels in the specialized rehabilitation robotics segment of the medical device market, leveraging technical differentiation and multi-country certifications.

In 2025, both revenue and net profit rose year over year, but the operating margin fell from 22.8% to 13.1%, and the company posted operating losses in three consecutive quarters from Q3 2025 through Q2 2026, reflecting increased volatility in recent quarterly results.

Operating cash flow also turned negative in 2025, sending a signal that diverges from the reported rise in accounting profit.

At the same time, the company retains notable strengths, including potential replacement demand following a leading global competitor's operational shutdown, product diversification through the upper-limb rehabilitation robot Healerbot, and a zero-debt financial structure.

With these bullish and bearish factors coexisting, upcoming quarterly results, the timing of any deferred revenue recognition, and progress on new overseas contracts are likely to be the key variables shaping the company's trajectory going forward.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.